RESEARCH MONOGRAPH · KDC-MN-305

Vinpocetine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

70/100

Synthetic vincamine derivative thats been a European nootropic standard for fifty years and is still confusingly under-studied in primates

Vinpocetine is the synthetic ethyl ester of apovincaminic acid, derived from the periwinkle alkaloid vincamine, developed in Hungary in the late 60s by Gedeon Richter as Cavinton. It's been a registered drug in much of Eastern Europe and Asia for cerebrovascular and cognitive indications for over fifty years, with the longest continuous clinical use record of pretty much any nootropic in our class. In the US it's a supplement, which is a regulatory anomaly that misrepresents what the clinical literature actually looks like.

The mechanism is multimodal and that's both interesting and a research liability. The cleanest established effects are PDE1 inhibition (which produces cerebrovascular vasodilation via increased cyclic GMP), sodium channel blockade in neurons (anti-seizure and anti-glutamate-excitotoxic activity), and improvement of cerebral blood flow without significant peripheral vasodilation. There's a secondary literature on noradrenaline release inhibition via SVOP transporter modulation that's more recent and less settled.

The clinical evidence is substantial but it's mostly older European trials, which means the methodology is variable and the modern meta-analysis quality is uneven. The Cochrane review of vinpocetine in cognitive impairment of vascular origin found inconclusive evidence by modern standards. Individual trials show modest cognitive and cerebrovascular improvements, particularly in elderly populations with documented cerebrovascular insufficiency, but the heterogeneity is real.

What we like: multi-decade safety record, well-characterized cerebrovascular mechanism, and a compound that's been used at scale long enough that the long-tail adverse event profile is well-understood. The acute cerebrovascular pharmacology in primate models is genuinely interesting.

What we dont love is the gap between the clinical use experience and the modern trial standards. Vinpocetine probably has real cognitive effects in vascular cognitive impairment but the trial methodology in most of the supporting literature wouldn't pass a contemporary regulatory review. And in healthy young adults the effect signal is much smaller, which the supplement-adjacent marketing tends to overstate.

Sourcing is okay. Pharma-grade vinpocetine is well-characterized, and research-grade material from competent suppliers lands above 98 percent HPLC reliably. The molecule is stable, achiral concerns are minimal, and the failure modes are typical for synthetic alkaloid derivatives.

Evidence: 60
Mechanism: 70
Reliability: 65
Safety: 80
Sourcing: 80
Value: 75
Signal: 65
Staying power: 65

Plain-language summary Intrigue 50 / 100

Vinpocetine (Cavinton) is a synthetic alkaloid derived from vincamine in the lesser periwinkle plant, developed at Gedeon Richter in Hungary in the 1960s. Approved across Europe for cerebrovascular insufficiency and used as a nootropic in the US (sold as a supplement). It works through several mechanisms at once: cerebral vasodilation, weak phosphodiesterase 1 inhibition, neuronal sodium channel block, and modest antioxidant activity, with the combined effect of improving blood flow to the brain. Clinical evidence in cognitive impairment and stroke recovery is mixed and dominated by older Eastern European trials with weak methodology. The FDA flagged it in 2019 over concerns about miscarriage in pregnant users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Synthetic vincamine derivative / cerebrovascular agent

A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

Abstract

Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

Mechanism of action

Cerebral vasodilation; weak PDE1 inhibition; sodium channel block; modest antioxidant activity. Improves cerebral blood flow.

Reported research dose ranges

Clinical 5 to 10 mg in the published literature. Rodent studies 1 to 10 mg/kg.

References

Bonoczk P, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 2000.
Patyar S, et al. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep 2011.
Szilagyi G, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke. J Neurol Sci 2005.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-305

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Vinpocetine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs